Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells

2.

Sun

W

,

Malvar

J

,

Sposto

R

, et al.

Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study

.

Leukemia

.

2018

;

32

(

11

):

2316

-

2325

.

doi:10.1038/s41375-018-0094-0

.

3.

Maude

SL

,

Frey

N

,

Shaw

PA

, et al.

Chimeric antigen receptor T cells for sustained remissions in leukemia

.

N Engl J Med

.

2014

;

371

(

16

):

1507

-

1517

.

doi:10.1056/NEJMoa1407222

.

4.

Maude

SL

,

Laetsch

TW

,

Buechner

J

, et al.

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

.

N Engl J Med

.

2018

;

378

(

5

):

439

-

448

.

doi:10.1056/NEJMoa1709866

.

5.

Gardner

RA

,

Finney

O

,

Annesley

C

, et al.

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

.

Blood

.

2017

;

129

(

25

):

3322

-

3331

.

doi:10.1182/blood-2017-02-769208

.

6.

Shah

NN

,

Lee

DW

,

Yates

B

, et al.

Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL

.

J Clin Oncol

.

2021

;

39

(

15

):

1650

-

1659

.

doi:10.1200/JCO.20.02262

.

7.

Jacoby

E

,

Bielorai

B

,

Hutt

D

, et al.

Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia

.

Br J Haematol

.

2022

;

197

(

4

):

475

-

481

.

doi:10.1111/bjh.18105

.

8.

Talleur

AC

,

Qudeimat

A

,

Métais

JY

, et al.

Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL

.

Blood Adv

.

2022

;

6

(

21

):

5737

-

5749

.

doi:10.1182/bloodadvances.2021006293

.

9.

Myers

RM

,

Taraseviciute

A

,

Steinberg

SM

, et al.

Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL

.

J Clin Oncol

.

2022

;

40

(

9

):

932

-

944

.

doi:10.1200/JCO.21.01405

.

10.

Schultz

LM

,

Baggott

C

,

Prabhu

S

, et al.

Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report

.

J Clin Oncol

.

2022

;

40

(

9

):

945

-

955

.

doi:10.1200/JCO.20.03585

.

11.

Ravich

JW

,

Huang

S

,

Zhou

Y

, et al.

Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel

.

Transplant Cell Ther

.

2022

;

28

(

2

):

73.e1

-

73.73.e9

.

doi:10.1016/j.jtct.2021.11.019

.

12.

Dourthe

ME

,

Rabian

F

,

Yakouben

K

, et al.

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

.

Leukemia

.

2021

;

35

(

12

):

3383

-

3393

.

doi:10.1038/s41375-021-01281-7

.

13.

Schultz

LM

,

Eaton

A

,

Baggott

C

, et al.

Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia

.

J Clin Oncol

.

2023

;

41

(

2

):

354

-

363

.

doi:10.1200/JCO.22.01076

.

14.

Schultz

L

,

Mackall

CL

.

The future of CAR T-cell therapy for B-cell acute lymphoblastic leukemia in pediatrics and adolescents

.

Expert Opin Biol Ther

.

2023

;

23

(

7

):

633

-

640

.

doi:10.1080/14712598.2023.2227086

.

15.

Fabrizio

VA

,

Kernan

NA

,

Boulad

F

, et al.

Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34- selected T-cell depleted allogeneic hematopoietic cell transplant

.

Bone Marrow Transpl

.

2020

;

55

(

11

):

2160

-

2169

.

doi:10.1038/s41409-020-0926-1

.

16.

Laetsch

TW

,

Maude

SL

,

Rives

S

, et al.

Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial

.

J Clin Oncol

.

2023

;

41

(

9

):

1664

-

1669

.

doi:10.1200/JCO.22.00642

.

17.

Pasquini

MC

,

Hu

ZH

,

Curran

K

, et al.

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

.

Blood Adv

.

2020

;

4

(

21

):

5414

-

5424

.

doi:10.1182/bloodadvances.2020003092

.

18.

Summers

C

,

Wu

QV

,

Annesley

C

, et al.

Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage

.

Transplant Cell Ther

.

2022

;

28

(

1

):

21

-

29

.

doi:10.1016/j.jtct.2021.10.003

.

19.

Jacoby

E

,

Ghorashian

S

,

Vormoor

B

, et al.

CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study

.

Leukemia

.

2022

;

36

(

6

):

1525

-

1532

.

doi:10.1038/s41375-022-01546-9

.

20.

Leahy

AB

,

Devine

KJ

,

Li

Y

, et al.

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

.

Blood

.

2022

;

139

(

14

):

2173

-

2185

.

doi:10.1182/blood.2021012727

.

21.

Laetsch

TW

,

Maude

SL

,

Balduzzi

A

, et al.

Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia

.

Leukemia

.

2022

;

36

(

6

):

1508

-

1515

.

doi:10.1038/s41375-022-01550-z

.

22.

Moskop

A

,

Pommert

L

,

Baggott

C

, et al.

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia

.

Blood Adv

.

2022

;

6

(

14

):

4251

-

4255

.

doi:10.1182/bloodadvances.2021006393

.

23.

Ghorashian

S

,

Jacoby

E

,

De Moerloose

B

, et al.

Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study

.

Lancet Haematol

.

2022

;

9

(

10

):

e766

-

e775

.

doi:10.1016/S2352-3026(22)00225-3

.

24.

Fabrizio

VA

,

Phillips

CL

,

Lane

A

, et al.

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a pediatric real world CAR consortium report

.

Blood Adv

.

2022

;

6

(

2

):

600

-

610

.

doi:10.1182/bloodadvances.2021005564

.

25.

Leahy

AB

,

Newman

H

,

Li

Y

, et al.

CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials

.

Lancet Haematol

.

2021

;

8

(

10

):

e711

-

e722

.

doi:10.1016/S2352-3026(21)00238-6

.

26.

Pulsipher

MA

,

Han

X

,

Maude

SL

, et al.

Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia

.

Blood Cancer Discov

.

2022

;

3

(

1

):

66

-

81

.

doi:10.1158/2643-3230.bcd-21-0095

.

27.

Abdel-Azim

H

,

Quigg

TC

,

Malvar

J

, et al.

Excellent relapse-free and overall survival in pre-HCT next-generation sequencing (NGS-MRD) negative B-ALL patients with or without TBI-based conditioning: outcome of the observational arm of the pediatric transplantation and cellular therapy consortium (PTCTC) ONC1701 endrad study

.

Transplant Cell Ther

.

2023

;

29

(

2

):

s94

-

S96

.

doi:10.1016/s2666-6367(23)00187-2

.

28.

Orlando

EJ

,

Han

X

,

Tribouley

C

, et al.

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

.

Nat Med

.

2018

;

24

(

10

):

1504

-

1506

.

doi:10.1038/s41591-018-0146-z

.

29.

Sotillo

E

,

Barrett

DM

,

Black

KL

, et al.

Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy

.

Cancer Discov

.

2015

;

5

(

12

):

1282

-

1295

.

doi:10.1158/2159-8290.CD-15-1020

.

30.

Gardner

R

,

Wu

D

,

Cherian

S

, et al.

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

.

Blood

.

2016

;

127

(

20

):

2406

-

2410

.

doi:10.1182/blood-2015-08-665547

.

31.

Lamble

AJ

,

Myers

RM

,

Taraseviciute

A

, et al.

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells

.

Blood Adv

.

2023

;

7

(

4

):

575

-

585

.

doi:10.1182/bloodadvances.2022007423

.

32.

Ruella

M

,

Xu

J

,

Barrett

DM

, et al.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

.

Nat Med

.

2018

;

24

(

10

):

1499

-

1503

.

doi:10.1038/s41591-018-0201-9

.

33.

Fry

TJ

,

Shah

NN

,

Orentas

RJ

, et al.

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

.

Nat Med

.

2018

;

24

(

1

):

20

-

28

.

doi:10.1038/nm.4441

.

34.

Shah

NN

,

Highfill

SL

,

Shalabi

H

, et al.

CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial

.

J Clin Oncol

.

2020

;

38

(

17

):

1938

-

1950

.

doi:10.1200/JCO.19.03279

.

35.

Spiegel

JY

,

Patel

S

,

Muffly

L

, et al.

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

.

Nat Med

.

2021

;

27

(

8

):

1419

-

1431

.

doi:10.1038/s41591-021-01436-0

.

36.

Cordoba

S

,

Onuoha

S

,

Thomas

S

, et al.

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

.

Nat Med

.

2021

;

27

(

10

):

1797

-

1805

.

doi:10.1038/s41591-021-01497-1

.

37.

Wang

T

,

Tang

Y

,

Cai

J

, et al.

Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial

.

J Clin Oncol

.

2023

;

41

(

9

):

1670

-

1683

.

doi:10.1200/jco.22.01214

.

38.

Qin

H

,

Cho

M

,

Haso

W

, et al.

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein

.

Blood

.

2015

;

126

(

5

):

629

-

639

.

doi:10.1182/blood-2014-11-612903

.

39.

Niswander

LM

,

Graff

ZT

,

Chien

CD

, et al.

Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia

.

Haematologica

.

2023

;

108

(

2

):

457

-

471

.

doi:10.3324/haematol.2022.281456

.

40.

Fousek

K

,

Watanabe

J

,

Joseph

SK

, et al.

CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression

.

Leukemia

.

2021

;

35

(

1

):

75

-

89

.

doi:10.1038/s41375-020-0792-2

.

41.

Wilson

TL

,

Kim

H

,

Chou

CH

, et al.

Common trajectories of highly effective CD19-specific CAR T cells identified by endogenous T-cell receptor lineages

.

Cancer Discov

.

2022

;

12

(

9

):

2098

-

2119

.

doi:10.1158/2159-8290.CD-21-1508

.

42.

Fraietta

JA

,

Lacey

SF

,

Orlando

EJ

, et al.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

.

Nat Med

.

2018

;

24

(

5

):

563

-

571

.

doi:10.1038/s41591-018-0010-1

.

43.

Finney

OC

,

Brakke

H

,

Rawlings-Rhea

S

, et al.

CD19 CAR T cell product and disease attributes predict leukemia remission durability

.

J Clin Invest

.

2019

;

129

(

5

):

2123

-

2132

.

doi:10.1172/JCI125423

.

44.

Chen

GM

,

Chen

C

,

Das

RK

, et al.

Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy

.

Cancer Discov

.

2021

;

11

(

9

):

2186

-

2199

.

doi:10.1158/2159-8290.CD-20-1677

.

45.

Anderson

ND

,

Birch

J

,

Accogli

T

, et al.

Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia

.

Nat Med

.

2023

;

29

(

7

):

1700

-

1709

.

doi:10.1038/s41591-023-02415-3

.

46.

Melenhorst

JJ

,

Chen

GM

,

Wang

M

, et al.

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

.

Nature

.

2022

;

602

(

7897

):

503

-

509

.

doi:10.1038/s41586-021-04390-6

.

47.

Li

AM

,

Hucks

GE

,

Dinofia

AM

, et al.

Checkpoint inhibitors augment CD19- directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia

.

Blood

.

2018

;

132

(

suppl 1

):

556

.

doi:10.1182/blood-2018-99-112572

.

48.

Michelozzi

IM

,

Gomez-Castaneda

E

,

Pohle

RVC

, et al.

Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells

.

Blood Adv

.

2023

;

7

(

9

):

1725

-

1738

.

doi:10.1182/bloodadvances.2022008490

.

49.

Ghorashian

S

,

Kramer

AM

,

Onuoha

S

, et al.

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

.

Nat Med

.

2019

;

25

(

9

):

1408

-

1414

.

doi:10.1038/s41591-019-0549-5

.

50.

Myers

RM

,

Li

Y

,

Barz Leahy

A

, et al.

Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia

.

J Clin Oncol

.

2021

;

39

(

27

):

3044

-

3055

.

doi:10.1200/JCO.20.03458

.

51.

Guedan

S

,

Posey

AD

Jr,

Shaw

C

, et al.

Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation

.

JCI Insight

.

2018

;

3

(

1

).

doi:10.1172/jci.insight.96976

.

52.

Chockley

PJ

,

Ibanez-Vega

J

,

Krenciute

G

,

Talbot

LJ

,

Gottschalk

S.

Synapse- tuned CARs enhance immune cell anti-tumor activity [published online ahead of print 2 February 2023]

.

Nat Biotechnol

.

doi:10.1038/s41587-022-01650-2

.

53.

Tousley

AM

,

Rotiroti

MC

,

Labanieh

L

, et al.

Co-opting signalling molecules enables logic-gated control of CAR T cells

.

Nature

.

2023

;

615

(

7952

):

507

-

516

.

doi:10.1038/s41586-023-05778-2

.

54.

Lynn

RC

,

Weber

EW

,

Sotillo

E

, et al.

c-Jun overexpression in CAR T cells induces exhaustion resistance

.

Nature

.

2019

;

576

(

7786

):

293

-

300

.

doi:10.1038/s41586-019-1805-z

.

55.

Wagner

J

,

Wickman

E

,

DeRenzo

C

,

Gottschalk

S.

CAR T cell therapy for solid tumors: bright future or dark reality?

Mol Ther

.

2020

;

28

(

11

):

2320

-

2339

.

doi:10.1016/j.ymthe.2020.09.015

.

56.

Labanieh

L

,

Mackall

CL

.

CAR immune cells: design principles, resistance and the next generation

.

Nature

.

2023

;

614

(

7949

):

635

-

648

.

doi:10.1038/s41586-023-05707-3

.

57.

Hoyos

V

,

Savoldo

B

,

Quintarelli

C

, et al.

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti- lymphoma/leukemia effects and safety

.

Leukemia

.

2010

;

24

(

6

):

1160

-

1170

.

doi:10.1038/leu.2010.75

.

58.

Wei

J

,

Long

L

,

Zheng

W

, et al.

Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy

.

Nature

.

2019

;

576

(

7787

):

471

-

476

.

doi:10.1038/s41586-019-1821-z

.

59.

Carnevale

J

,

Shifrut

E

,

Kale

N

, et al.

RASA2 ablation in T cells boosts antigen sensitivity and long-term function

.

Nature

.

2022

;

609

(

7925

):

174

-

182

.

doi:10.1038/s41586-022-05126-w

.

60.

Fraietta

JA

,

Nobles

CL

,

Sammons

MA

, et al.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

.

Nature

.

2018

;

558

(

7709

):

307

-

312

.

doi:10.1038/s41586-018-0178-z

.

61.

Prinzing

B

,

Zebley

CC

,

Petersen

CT

, et al.

Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

.

Sci Transl Med

.

2021

;

13

(

620

):

eabh0272

.

doi:10.1126/scitranslmed.abh0272

.

62.

Jain

N

,

Zhao

Z

,

Feucht

J

, et al.

TET2 guards against unchecked BATF3- induced CAR T cell expansion

.

Nature

.

2023

;

615

(

7951

):

315

-

322

.

doi:10.1038/s41586-022-05692-z

.

63.

Rafiq

S

,

Hackett

CS

,

Brentjens

RJ

.

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

.

Nat Rev Clin Oncol

.

2020

;

17

(

3

):

147

-

167

.

doi:10.1038/s41571-019-0297-y

.